TRAVERE THERAPEUTICS INC

Explore how Gary A. Lyons’ recent trades at Travere Therapeutics signal insider confidence, boost social chatter, and shape the stock’s rally.

Baynes Roy D. buys 4,500 Travere Therapeutics shares amid strong market momentum, signaling insider confidence in the company’s rare‑disease pipeline.

Insider buying of Travere Therapeutics shares signals management confidence in its rare‑disease pipeline, driving bullish sentiment and potential upside for investors.

Insider buying at Travere Therapeutics spikes after FDA approval of FILSPARI, with the Chief Commercial Officer adding 14,000 shares—signaling strong leadership confidence and potential upside for investors.

Discover how Travere Therapeutics’ insider trades reveal cautious optimism and strategic long‑term confidence.

Travere insider trading shows confidence: Baynes Roy D buys 10K shares, sells options at a 25 % premium, while execs continue balanced buying/selling amid rising clinical prospects.

Insider trades at Travere Therapeutics reveal a disciplined “sell‑after‑exercise” strategy, blending discounted option purchases with near‑market sales that signal confidence in upcoming milestones while managing liquidity.

CEO Eric Dube’s recent $15.46‑per‑share buy at Travere Therapeutics shows insider confidence amid a rally, hinting at future growth in rare‑disease biotech.

Travere insider buys signal confidence: Chief Legal Officer’s 10,000‑share purchase below market shows long‑term optimism amid upcoming earnings.

Reed’s $19.08 buy at Travere Therapeutics signals insider confidence despite recent selling, hinting at a potential upside driven by future pipeline milestones.